<DOC>
	<DOCNO>NCT00003575</DOCNO>
	<brief_summary>Phase II trial compare effectiveness interleukin-12 follow chemotherapy treat patient refractory HIV-associated non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person ' white blood cell kill cancer cell .</brief_summary>
	<brief_title>Interleukin-12 Following Chemotherapy Treating Patients With Refractory HIV-Associated Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy interleukin-12 ( IL-12 ) evaluate effect remission duration response second line chemotherapy ifosfamide etoposide patient HIV-associated non-Hodgkin 's lymphoma . II . Determine safety IL-12 administer maintenance therapy patient . III . Evaluate overall survival patient population . IV . Evaluate serum tissue cytokine level patient . V. Evaluate effect IL-12 HIV viral load functional T-cell assay patient . VI . Evaluate effect IL-12 Epstein-Barr Virus ( EBV ) viral load patient . OUTLINE : This open label study . All patient receive ifosfamide IV continuous infusion 2 day , etoposide IV 2 hour daily day 1 2 , filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 4-13 . Courses repeat every 21 day . Patients complete partial remission minimum 4 course chemotherapy receive maintenance therapy consist interleukin-12 SC twice weekly begin day 28 final chemotherapy course continue 6 month disease progression . All patient also receive combination antiretroviral therapy study . Patients follow every month one year , every 2 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIVinfected patient histologically cytologically proven intermediate grade large cell lymphoma ; high grade large cell immunoblastic lymphoma ; high grade small noncleaved cell lymphoma either fail respond relapse follow first line combination chemotherapy Bidimensionally measurable disease No CNS lymphoma ( parenchymal brain spinal cord tumor ) No meningeal lymphoma A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Karnofsky 60100 % Absolute neutrophil count least 1,000/mm3 Platelet count great 75,000/mm3 Hematologic criterion applicable abnormal function attributable lymphomatous infiltration bone marrow liver Bilirubin le 2.0 mg/dL , except patient receive indinavir isolate hyperbilirubinemia Transaminases less 5 time upper limit normal Hepatic criterion applicable abnormal function attributable lymphomatous infiltration bone marrow liver Creatinine clearance great 60 mL/min No prior concurrent malignancy except carcinoma situ cervix nonmetastatic nonmelanomatous skin cancer No acute active opportunistic infection require antibiotic treatment Patients Mycobacterium avium complex allow Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 2 week since prior immunomodulating agent Concurrent filgrastim ( GCSF ) allow Concurrent epoetin alfa allow Concurrent antibiotic may give clinically indicate study No 2 prior standard treatment regimens nonHodgkin 's lymphoma No concurrent systemic corticosteroid Concurrent topical and/or oral antifungal agent permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
</DOC>